Literature DB >> 33413127

Prognostic value of pro-adrenomedullin and copeptin in acute infective endocarditis.

Rosa Zampino1,2, Domenico Iossa3, Maria Paola Ursi1, Lorenzo Bertolino1, Roberto Andini2, Rosa Molaro3, Oriana Fabrazzo1, Silvia Leonardi4, Luigi Atripaldi4, Emanuele Durante-Mangoni5,6.   

Abstract

BACKGROUND: Infective endocarditis (IE) is a life-threatening disease whose prognosis is often difficult to predict based on clinical data. Biomarkers have been shown to favorably affect disease management in a number of cardiac disorders. Aims of this retrospective study were to assess the prognostic role of procalcitonin (PCT), pro-adrenomedullin (pro-ADM) and copeptin in IE and their relation with disease characteristics and the traditional biomarker C-reactive protein (CRP).
METHODS: We studied 196 patients with definite IE. Clinical, laboratory and echocardiography parameters were analyzed, with a focus on co-morbidities. PCT, pro-ADM and copeptin were measured on stored plasma samples obtained on admission during the acute phase of the disease.
RESULTS: Pro-ADM and copeptin were significantly higher in older patients and associated with prior chronic kidney disease. Pro-ADM was an independent predictor of hospital mortality (OR 3.29 [95%C.I. 1.04-11.5]; p = 0.042) whilst copeptin independently predicted 1-year mortality (OR 2.55 [95%C.I. 1.18-5.54]; p = 0.017). A high PCT value was strictly tied with S. aureus etiology (p = 0.001). CRP was the only biomarker associated with embolic events (p = 0.003).
CONCLUSIONS: Different biomarkers correlate with distinct IE outcomes. Pro-ADM and copeptin may signal a worse prognosis of IE on admission to the hospital and could be used to identify patients who need more aggressive treatment. CRP remains a low-cost marker of embolic risk. A high PCT value should suggest S. aureus etiology.

Entities:  

Keywords:  Biomarkers; Heart failure; Heart valve disease; Mortality; Organ dysfunction

Mesh:

Substances:

Year:  2021        PMID: 33413127      PMCID: PMC7791699          DOI: 10.1186/s12879-020-05655-7

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  28 in total

1.  Usefulness of procalcitonin for diagnosis of infective endocarditis.

Authors:  Matjaz Jereb; Tadeja Kotar; Tomaz Jurca; Tatjana Lejko Zupanc
Journal:  Intern Emerg Med       Date:  2009-04-09       Impact factor: 3.397

Review 2.  C-reactive protein and cardiovascular disease: new insights from an old molecule.

Authors:  G M Hirschfield; M B Pepys
Journal:  QJM       Date:  2003-11

3.  High serum procalcitonin concentrations in patients with sepsis and infection.

Authors:  M Assicot; D Gendrel; H Carsin; J Raymond; J Guilbaud; C Bohuon
Journal:  Lancet       Date:  1993-02-27       Impact factor: 79.321

Review 4.  Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis.

Authors:  Christina Wacker; Anna Prkno; Frank M Brunkhorst; Peter Schlattmann
Journal:  Lancet Infect Dis       Date:  2013-02-01       Impact factor: 25.071

5.  Vasopressin and copeptin levels in children with sepsis and septic shock.

Authors:  Jan Hau Lee; Yoke Hwee Chan; Oi Fah Lai; Janil Puthucheary
Journal:  Intensive Care Med       Date:  2013-01-24       Impact factor: 17.440

6.  Risk factors for "major" embolic events in hospitalized patients with infective endocarditis.

Authors:  Emanuele Durante Mangoni; Luigi E Adinolfi; Marie-Francoise Tripodi; Augusto Andreana; Michele Gambardella; Enrico Ragone; Davide F Precone; Riccardo Utili; Giuseppe Ruggiero
Journal:  Am Heart J       Date:  2003-08       Impact factor: 4.749

7.  Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.

Authors:  Evelien de Jong; Jos A van Oers; Albertus Beishuizen; Piet Vos; Wytze J Vermeijden; Lenneke E Haas; Bert G Loef; Tom Dormans; Gertrude C van Melsen; Yvette C Kluiters; Hans Kemperman; Maarten J van den Elsen; Jeroen A Schouten; Jörn O Streefkerk; Hans G Krabbe; Hans Kieft; Georg H Kluge; Veerle C van Dam; Joost van Pelt; Laura Bormans; Martine Bokelman Otten; Auke C Reidinga; Henrik Endeman; Jos W Twisk; Ewoudt M W van de Garde; Anne Marie G A de Smet; Jozef Kesecioglu; Armand R Girbes; Maarten W Nijsten; Dylan W de Lange
Journal:  Lancet Infect Dis       Date:  2016-03-02       Impact factor: 25.071

8.  Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study.

Authors:  Mirjam Christ-Crain; Nils G Morgenthaler; Joachim Struck; Stephan Harbarth; Andreas Bergmann; Beat Müller
Journal:  Crit Care       Date:  2005-11-15       Impact factor: 9.097

9.  Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients.

Authors:  Philipp Schuetz; Paula Maurer; Vikas Punjabi; Ami Desai; Devendra N Amin; Eric Gluck
Journal:  Crit Care       Date:  2013-06-20       Impact factor: 9.097

10.  Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients.

Authors:  Oscar H M Lundberg; Lill Bergenzaun; Jörgen Rydén; Mari Rosenqvist; Olle Melander; Michelle S Chew
Journal:  Crit Care       Date:  2016-06-09       Impact factor: 9.097

View more
  3 in total

1.  Dissecting the correlates of N-terminal prohormone brain natriuretic peptide in acute infective endocarditis.

Authors:  Lorenzo Bertolino; Maria Paola Ursi; Domenico Iossa; Arta Karruli; Fabiana D'Amico; Rosa Zampino; Giovanni Dialetto; Marisa De Feo; Emanuele Durante-Mangoni
Journal:  Infection       Date:  2022-04-16       Impact factor: 7.455

Review 2.  Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.

Authors:  Toshihiro Kita; Kazuo Kitamura
Journal:  Hypertens Res       Date:  2022-01-06       Impact factor: 5.528

3.  Prognostic Value of Decreased High-Density Lipoprotein Cholesterol Levels in Infective Endocarditis.

Authors:  Rosa Zampino; Fabian Patauner; Arta Karruli; Domenico Iossa; Maria Paola Ursi; Lorenzo Bertolino; Anna Maria Peluso; Fabiana D'Amico; Giusi Cavezza; Emanuele Durante-Mangoni
Journal:  J Clin Med       Date:  2022-02-12       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.